刊物主题:Oncology; Pharmacology/Toxicology; Cancer Research;
出版者:Springer Berlin Heidelberg
ISSN:1432-0843
卷排序:79
文摘
PurposeSkin toxicity (ST) and early tumor shrinkage (ETS) are early phenomenon during the anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb) treatment. We conducted a meta-analysis and included relevant studies that reported the impact of ST and ETS on survival- and life quality-based outcome of metastatic colorectal cancer (mCRC) patients treated with anti-EGFR MoAb.